Our specialized viral vector contract development and manufacturing organization (CDMO) services provide end-to-end solutions for next-generation biological interventions. Leveraging expertise in complex biologics, we accelerate your program from concept to manufacturing. Explore our broader capabilities in CDMO Solutions.
Introduction to Viral Vector
Viral vectors harness evolved transduction mechanisms to deliver genetic material with high efficiency. These engineered viruses retain infectivity while lacking replication competence, making them indispensable tools for targeted biological applications. Key categories include integrating vectors (e.g., lentivirus, retrovirus) for sustained genetic modification and non-integrating systems (e.g., adenovirus) for transient expression. Critical attributes like tropism, payload capacity, and immunogenicity dictate therapeutic suitability. Our platform addresses inherent challenges in vector design, including genome stability, capsid engineering, and scalable production, ensuring optimal functionality for diverse clinical objectives.
Our Viral Vector CDMO Solutions
Lentiviral Vector (LV) CDMO Solutions
Lentiviral vectors (LVs), derived from modified lentiviruses (notably HIV-1), possess distinct advantages for genetic medicine.Our lentiviral platform supports stable genomic integration applications. We optimize third-generation packaging systems with inducible promoters and self-inactivating (SIN) designs to enhance safety profiles. Our expertise spans process and analytical development, scalable cGMP manufacturing, and comprehensive regulatory support.
Adeno-associated Virus (AAV) CDMO Solutions
AAV vectors have emerged as leading vehicles for gene-based therapeutic interventions due to their favorable safety characteristics, sustained expression profiles, and adaptable tissue targeting.We accelerate adeno-associated virus (AAV) therapeutic development through integrated CDMO expertise: vector design, scalable GMP manufacturing, and analytical excellence. Our end-to-end solutions translate science into clinical reality with robust quality and efficiency.
Retroviral (RV) CDMO Solutions
RV vectors harness the natural ability of retroviridae to integrate genetic material into host genomes, enabling durable modifications in target cells. These vectors are engineered to eliminate replication competence while retaining high transduction efficiency.We deliver end-to-end retroviral vector CDMO solutions, from genotoxicity-mitigated vector design to scalable GMP manufacturing.
Modified Vaccinia Ankara (MVA) CDMO Solutions
MVA represents a highly attenuated strain of vaccinia virus, extensively passaged in avian cells, resulting in significant genomic deletions that render it replication-deficient in mammalian cells.We deliver end-to-end modified vaccinia ankara (MVA) CDMO solutions, from precision vector design to scalable GMP manufacturing. Leveraging deep poxvirus expertise, we accelerate your development timeline while de-risking technical challenges.
Virus-Like Particle (VLP) CDMO Solutions
VLPs represent a sophisticated class of nanostructures, meticulously designed to emulate the structural conformation of native viruses while lacking functional genetic material. We deliver integrated virus-like particle CDMO solutions, leveraging cutting-edge molecular design, process development, and GMP manufacturing expertise.
Frequently Asked Questions
Q1: What distinguishes your AAV manufacturing platform?
Our dual-approach (mammalian and baculovirus systems) provides flexibility for serotype-specific yield optimization. We prioritize capsid integrity through proprietary purification methods – critical for dosing accuracy and reduced immunogenicity.
Q2: How do you address lentiviral vector biosafety concerns?
All lentiviral processes use third-generation split-genome plasmids with SIN LTRs and codon-optimuted gag/pol. We implement rigorous replication-competent lentivirus (RCL) testing via sensitive qPCR assays and comply with related guidelines for adventitious agent control.
Q3: What analytical capabilities ensure vector quality?
Platform methods include ddPCR for genome titering, HPLC-SEC for aggregation analysis, TCID50 for infectivity, and mass spectrometry for capsid protein ratios. We develop product-specific assays for transduction efficiency and impurity profiling (host cell proteins, residual plasmids).
Q4: Do you offer construct optimization services?
Absolutely. Our vectorology team provides promoter/enhancer screening, transgene codon optimization, ITR engineering for AAV, and insertion site validation to maximize expression kinetics and minimize silencing risks.
Our products and services are for research use only.
